[SCHEDULE 13G] iBio, Inc. Passive Investment Disclosure (>5%)
Lynx1 reports 5.4% iBio stake via Series F warrants
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of iBio, Inc. common stock through Series F warrants held by Lynx1 Master Fund LP.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of iBio, Inc. common stock through Series F warrants held by Lynx1 Master Fund LP. They report beneficial ownership of 2,807,016 shares of common stock issuable upon exercise of these warrants, which are subject to a 9.99% Blocker limiting exercisability. Based on 49,678,561 shares of common stock outstanding as of May 12, 2026, and assuming exercise of the warrants, this represents 5.4% of the class. The filers note that a prior Schedule 13G filed on February 17, 2026 inadvertently excluded these warrants from their reported beneficial ownership.
Key Figures
Beneficially owned shares:2,807,016 sharesPercent of class:5.4%Shares outstanding:49,678,561 shares+1 more
4 metrics
Beneficially owned shares2,807,016 sharesShares of common stock issuable upon exercise of Series F warrants reported by the Reporting Persons
Percent of class5.4%Beneficial ownership of iBio common stock based on 49,678,561 shares outstanding as of May 12, 2026
Shares outstanding49,678,561 sharesiBio common stock outstanding as of May 12, 2026 used to calculate ownership percentage
Beneficial ownership limiter9.99%Ownership cap in the 9.99% Blocker governing exercisability of the Series F warrants
Key Terms
beneficial ownership, Series F warrants, 9.99% Blocker, Schedule 13G, +1 more
5 terms
beneficial ownershipregulatory
"for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Series F warrantsfinancial
"Includes 2,807,016 shares of Common Stock issuable upon the exercise of Series F warrants"
Series F warrants are a specific tranche of warrants issued by a company that give the holder the right to buy a set number of common shares at a predetermined price before the warrants expire; the “Series F” label distinguishes this issuance from other warrant tranches. They matter to investors because if holders exercise them the company’s share count increases, which can change ownership percentages and affect per-share value—similar to more people entering a venue and reducing each person’s share of the seats.
9.99% Blockerfinancial
"Series F warrants (the "Warrants"), which are subject to a 9.99% blocker (the "9.99% Blocker")"
Schedule 13Gregulatory
"The Reporting Person's previous Schedule G filing on February 17, 2026 inadvertently excluded these Warrants"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
shared voting powerfinancial
"Shared Voting Power 2,807,016.00 7 | Sole Dispositive Power 0.00 8 | Shared Dispositive Power 2,807,016.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in iBio (IBIO) does Lynx1 Capital Management report?
Lynx1 Capital Management and Weston Nichols report beneficial ownership of 5.4% of iBio’s common stock, based on 49,678,561 shares outstanding as of May 12, 2026 and assuming exercise of their warrants.
How many iBio (IBIO) shares are linked to Lynx1’s Series F warrants?
The filing states that Lynx1’s position includes 2,807,016 shares of iBio common stock issuable upon exercise of Series F warrants, all of which are subject to a 9.99% ownership blocker on exercise.
What is the significance of the 9.99% Blocker in the iBio (IBIO) filing?
The 9.99% Blocker limits exercise of Lynx1’s Series F warrants so that their beneficial ownership of iBio common stock does not exceed 9.99%, constraining how many warrant shares can be exercised at any time.
Why did Lynx1 amend its Schedule 13G for iBio (IBIO)?
Lynx1 Capital Management and Weston Nichols disclose that their February 17, 2026 Schedule 13G inadvertently excluded the Series F warrants, and this filing corrects their reported beneficial ownership to include 2,807,016 warrant shares.
Who is deemed the beneficial owner of the reported iBio (IBIO) shares?
The filing identifies Lynx1 Capital Management LP and Weston Nichols as Reporting Persons with shared voting and dispositive power over 2,807,016 shares, while clarifying it should not be construed as an admission of beneficial ownership for all purposes.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
iBio, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
451033708
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
451033708
1
Names of Reporting Persons
Lynx1 Capital Management LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,807,016.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,807,016.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,807,016.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: Includes 2,807,016 shares of Common Stock (as defined in Item 2(a)) issuable upon the exercise of Series F warrants (the "Warrants"), which are subject to a 9.99% blocker (the "9.99% Blocker"). The Reporting Person's previous Schedule G filing on February 17, 2026 inadvertently excluded these Warrants from the Reporting Persons' beneficial ownership.
SCHEDULE 13G
CUSIP Number(s):
451033708
1
Names of Reporting Persons
Weston Nichols
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,807,016.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,807,016.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,807,016.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Includes 2,807,016 shares of Common Stock issuable upon exercise of the Warrants, which are subject to a 9.99% Blocker. The Reporting Person's previous Schedule G filing on February 17, 2026 inadvertently excluded these Warrants from the Reporting Persons' beneficial ownership.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
iBio, Inc.
(b)
Address of issuer's principal executive offices:
11750 Sorrento Valley Road, Suite 200, San Diego, California 92121
Item 2.
(a)
Name of person filing:
(i) Lynx1 Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the "Lynx1 Fund"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of iBio, Inc., a Delaware corporation, that were directly held by the Lynx1 Fund; and
(ii) Mr. Weston Nichols ("Mr. Nichols"), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock that were directly held by the Lynx1 Fund.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
Lynx1 Capital Management LP
D81 Calle C
Suite 301, PMB 1202
Dorado, PR, 00646-2051
Weston Nichols
c/o Lynx1 Capital Management LP
D81 Calle C
Suite 301, PMB 1202
Dorado, PR, 00646-2051
(c)
Citizenship:
Investment Manager - Delaware
Mr. Nichols - United States of America
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP Number(s):
451033708
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 49,678,561 shares of Common Stock outstanding as of May 12, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 12, 2026 and assumes the exercise of the Warrants held by the Lynx1 Fund.
(b)
Percent of class:
5.4%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Lynx1 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Lynx1 Capital Management LP
Signature:
/s/ Weston Nichols
Name/Title:
By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
